Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors

Simron Singh, Lesley Moody, David L. Chan, David C. Metz, Jonathan Strosberg, Timothy Asmis, Dale L. Bailey, Emily Bergsland, Kari Brendtro, Richard Carroll, Sean Cleary, Michelle Kim, Grace Kong, Calvin Law, Ben Lawrence, Alexander McEwan, Caitlin McGregor, Michael Michael, Janice Pasieka, Nick Pavlakis & 4 others Rodney Pommier, Michael Soulen, David Wyld, Eva Segelov

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm..

Original languageEnglish
Pages (from-to)1597-1604
Number of pages8
JournalJAMA Oncology
Volume4
Issue number11
DOIs
Publication statusPublished - 1 Nov 2018

Cite this

Singh, Simron ; Moody, Lesley ; Chan, David L. ; Metz, David C. ; Strosberg, Jonathan ; Asmis, Timothy ; Bailey, Dale L. ; Bergsland, Emily ; Brendtro, Kari ; Carroll, Richard ; Cleary, Sean ; Kim, Michelle ; Kong, Grace ; Law, Calvin ; Lawrence, Ben ; McEwan, Alexander ; McGregor, Caitlin ; Michael, Michael ; Pasieka, Janice ; Pavlakis, Nick ; Pommier, Rodney ; Soulen, Michael ; Wyld, David ; Segelov, Eva. / Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. In: JAMA Oncology. 2018 ; Vol. 4, No. 11. pp. 1597-1604.
@article{d146884f78f94ab18910a716fac2656a,
title = "Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors",
abstract = "There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm..",
author = "Simron Singh and Lesley Moody and Chan, {David L.} and Metz, {David C.} and Jonathan Strosberg and Timothy Asmis and Bailey, {Dale L.} and Emily Bergsland and Kari Brendtro and Richard Carroll and Sean Cleary and Michelle Kim and Grace Kong and Calvin Law and Ben Lawrence and Alexander McEwan and Caitlin McGregor and Michael Michael and Janice Pasieka and Nick Pavlakis and Rodney Pommier and Michael Soulen and David Wyld and Eva Segelov",
year = "2018",
month = "11",
day = "1",
doi = "10.1001/jamaoncol.2018.2428",
language = "English",
volume = "4",
pages = "1597--1604",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association (AMA)",
number = "11",

}

Singh, S, Moody, L, Chan, DL, Metz, DC, Strosberg, J, Asmis, T, Bailey, DL, Bergsland, E, Brendtro, K, Carroll, R, Cleary, S, Kim, M, Kong, G, Law, C, Lawrence, B, McEwan, A, McGregor, C, Michael, M, Pasieka, J, Pavlakis, N, Pommier, R, Soulen, M, Wyld, D & Segelov, E 2018, 'Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors', JAMA Oncology, vol. 4, no. 11, pp. 1597-1604. https://doi.org/10.1001/jamaoncol.2018.2428

Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. / Singh, Simron; Moody, Lesley; Chan, David L.; Metz, David C.; Strosberg, Jonathan; Asmis, Timothy; Bailey, Dale L.; Bergsland, Emily; Brendtro, Kari; Carroll, Richard; Cleary, Sean; Kim, Michelle; Kong, Grace; Law, Calvin; Lawrence, Ben; McEwan, Alexander; McGregor, Caitlin; Michael, Michael; Pasieka, Janice; Pavlakis, Nick; Pommier, Rodney; Soulen, Michael; Wyld, David; Segelov, Eva.

In: JAMA Oncology, Vol. 4, No. 11, 01.11.2018, p. 1597-1604.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors

AU - Singh, Simron

AU - Moody, Lesley

AU - Chan, David L.

AU - Metz, David C.

AU - Strosberg, Jonathan

AU - Asmis, Timothy

AU - Bailey, Dale L.

AU - Bergsland, Emily

AU - Brendtro, Kari

AU - Carroll, Richard

AU - Cleary, Sean

AU - Kim, Michelle

AU - Kong, Grace

AU - Law, Calvin

AU - Lawrence, Ben

AU - McEwan, Alexander

AU - McGregor, Caitlin

AU - Michael, Michael

AU - Pasieka, Janice

AU - Pavlakis, Nick

AU - Pommier, Rodney

AU - Soulen, Michael

AU - Wyld, David

AU - Segelov, Eva

PY - 2018/11/1

Y1 - 2018/11/1

N2 - There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm..

AB - There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm..

UR - http://www.scopus.com/inward/record.url?scp=85052725843&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.2428

DO - 10.1001/jamaoncol.2018.2428

M3 - Article

VL - 4

SP - 1597

EP - 1604

JO - JAMA Oncology

JF - JAMA Oncology

SN - 2374-2437

IS - 11

ER -